Introduction
T he use of human tumor xenografts in immunodeficient mice has provided significant insight into the biology of tumor growth and metastasis and has enabled scientists to study the complex biology of human tumor growth more effectively. Work from our laboratory and others' supports the notion that net tumor-derived angiogenesis during tumorigenesis of human tumors is determined, in part, by an imbalance in favor of the overexpression of angiogenic compared with angiostatic CXC chemokines ( Figure 1 ). This paradigm predicts an environment that favors angiogenesis and tumorigenesis and supports the potential for spontaneous metastases. The purpose of this article is to describe the use of immunodeficient mice as an animal model system to characterize the qualitative and quantitative presence of these angiogenic and angiostatic CXC chemokines during tumorigenesis and to determine their net contribution to human tumorigenesis and metastasis in vivo. Various cancer cell lines have been used and xenografted into immunodeficient mice (such as severe combined immunodeficiency [SCID 1 ] or nude mice) to create a human tumor/mouse chimeras. The results of these studies have provided evidence that an imbalance in the biology of angiogenic versus angiostatic CXC chemokines supports a significant portion of human tumorderived angiogenesis leading to augmented tumorigenesis and spontaneous metastases. Moreover, using the immunodeficient mouse model system has made possible the identification of potential novel strategies to manipulate therapeutically the imbalance of angiogenic compared with angiostatic CXC chemokines, which may be directly translational to human disease.
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Figure 1
Net tumor-derived angiogenesis during tumorigenesis is determined, in part, by an imbalance in favor of the overexpression of angiogenic (ELR + ), compared with angiostatic (ELR~) CXC chemokines. This paradigm predicts an environment that favors angiogenesis, and tumorigenesis and supports the potential for spontaneous metastases. In contrast, this paradigm also supports the contention that inhibition of angiogenic or augmentation of angiostatic CXC chemokine biology will lead to reduced tumor growth and metastases. Polverini and others 1977) . The regulation of angiogenesis depends on a dual, yet opposing, balance of local factors that promote or inhibit neovascularization. For example, the rate of normal capillary endothelial cell turnover in adults is typically measured in months or years (Engerman and others 1967; Tannock and Hayashi 1972) , suggesting a balance between angiogenic and angiostatic factors under homeostatic conditions. By contrast, the development of granulation tissue of wounds shifts the balance in favor of a predominance of angiogenic factors leading to new functioning capillaries within a matter of days (Leibovich and Weisman 1988) . Angiogenesis of wound granulation tissue is locally controlled and transient. These qualities support the notion that the following process occurs in wound granulation tissue: a marked reduction in the elaboration of angiogenic factors and/or a simultaneous increase in the level of factors that inhibit neovascularization (Bouck 1992) . In contrast to the precise regulation in wound repair, dysregulation of angiogenesis can lead to an imbalance in the relationship of angiogenic and angiostatic factors, which favors persistent net angiogenesis that contributes to the pathogenesis of tumor growth and metastases. The complement of angiogenic and angiostatic factors may vary among different physiological and pathological settings. However, the recognition of this dual mechanism of control is critical to gain insight into this complex process and understand the regulation of angiogenesis in association with tumorigenesis.
CXC Chemokine Family of Cytokines
A variety of factors have been described that promote angiogenesis (Auerbach 1981; Folkman 1985 Folkman , 1993 Folkman , 1996 Folkman , 1997 Folkman , 1998 Folkman and Brem 1992; Folkman and Klagsbrun 1987; Gastl and others 1997; Hotfilder and others 1997; Hui and Ignoffo 1998; Kumar and Fidler 1998; Lund and others 1998; Pluda 1997; Risau 1997; Zetter 1998; Ziche and others 1996) . Perhaps the best studied of the angiogenic factors are vascular endothelial growth factor (VEGF 1 ) and basic fibroblast growth factor (bFGF 1 ) (Gastl and others 1997; Hotfilder and others 1997; Hui and Ignoffo 1998; Kumar and Fidler 1998; Lund and others 1998; Pluda 1997; Risau 1997; Zetter 1998; Ziche and others 1996) . In contrast, both angiostatin and endostatin have been found to display marked inhibition of angiogenesis others 1994,1997) . Although these factors are important in the regulation of angiogenesis in both physiological and pathophysiological processes, these molecules do not fully account for all of the modulation of the neovascular response in pathological conditions, such as tumorigenesis.
CXC chemokines are characteristically heparin binding proteins. On a structural level, they have four highly conserved cysteine amino acid residues, with the first two cysteines separated by one nonconserved amino acid residue, hence the name CXC (Adams and Lloyd 1997; Baggiolini 1998; Baggiolini and others 1994; Baggiolini and others 1997; Balkwill 1998; Luster 1998; Rollins 1997; Strieter and Kunkel 1997; Taub and Oppenheim 1994; Walz and others 1996) . Although the CXC motif distinguishes this family from other chemokine families, a second structural domain within this family dictates their angiogenic potential. The NH 2 -terminus of the majority of the CXC chemokines containing three amino acid residues (Glu-Leu-Arg: the "ELR" motif) precedes the first cysteine amino acid residue of the primary structure of these cytokines (Adams and Lloyd 1997; Baggiolini 1998; Baggiolini and others 1994,1997; Balkwill 1998; Luster 1998; Rollins 1997; Strieter and Kunkel 1997; Taub and Oppenheim 1994; Walz and others 1996) . The family members that contain the ELR motif (ELR + ) are potent promoters of angiogenesis in physiological concentrations of 1 to 10 nM (Strieter and others 1995) (Table 1 ). In contrast, members that lack the ELR motif (ELR") are potent inhibitors of angiogenesis in physiological concentrations of 500 pM to 1 nM (Strieter and others 1995) . This difference suggests on a structural/functional level that members of the CXC chemokine family are unique cytokines in their ability to behave in a disparate manner in the regulation of angiogenesis. The angiogenic members include interleukin (EL 1 )^, epithelial neutrophil activating protein (ENA 1 )-78, growthrelated oncogenes (GRO^a, P, and y), granulocyte chemotactic protein-2, and NHj-terminal truncated forms of platelet basic protein (PBP 1 ), which include connective tissue activating protein-III, beta-thromboglobulin, and neutrophil activating protein-2 (Hu and others 1993; Koch and others 1992; others 1992, 1995) .
The angiostatic (ELR") members of the CXC chemokine family include platelet factor-4 (PF4) (Thomas and others 1970) , monokine induced by interferon-y (MIG 1 ) (Farber 1992 (Farber , 1993 (Farber , 1990 (Farber , 1997 , and interferon (IFNO-y-inducible protein (IP^-IO (Farber 1990 (Farber , 1992 (Farber , 1993 (Farber , 1997 Luster and Ravetch 1987; Luster and others 1985) (Table 1) . Although interferon-inducible T-cell alpha chemoattractant and stromal cell-derived factor (SDF 1 )-! are additional ELR-CXC chemokines, it remains unclear whether they inhibit angiogenesis. SDF-1 has been found to induce in vitro migration of human umbilical vein endothelial cells (Gupta and others 1998) . In contrast, SDF-1 has also been found to attenuate the in vivo angiogenic activity of either ELR + CXC chemokines, bFGF, or VEGF using the rat cornea micropocket (CMP 1 ) assay of neovascularization (Arenberg and others 1997) . IP-10 can be induced by all three interferons (IFN-a, p\ and y) (Farber 1990 (Farber , 1992 (Farber , 1993 (Farber , 1997 Luster 1998; Luster and Ravetch 1987; Luster and others 1985) . MIG is unique in that it is only induced by IFN-y (Farber 1992 (Farber , 1993 (Farber , 1990 (Farber , 1997 Luster 1998; Luster and Ravetch 1987; Luster and others 1985) . Therefore, interferons and other cytokines that can induce the expression of interferons (IL-12 and IL-18) may have a profound effect on the production of IP-10 and MIG (Table 2) . Although interferons induce the production of the angiostatic CXC chemokines IP-10 and MIG, they attenuate the expression of the angiogenic CXC chemokines IL-8, GRO-y, and ENA-78 (Gusella and others 1993; Schnyder-Candrian and others 1995) (Table  2 ). This differential regulation of angiostatic versus angiogenic CXC chemokines by interferons may, in part, account for their previously documented inhibitory effect on angiogenesis (Angiolillo and others 1996; Coughlin and others 1998; Folkman 1997; Majewski and others 1996; Sgadari and others 1996; Vizier and others 1998; Zetter 1998) .
CXC Chemokines Are Potent Regulators of Angiogenesis
PF4 (ELR~) was the first CXC chemokine reported to regulate angiogenesis. PF4 was found to inhibit bFGF-induced angiogenesis and attenuate growth of melanoma and colon carcinomas in a murine model of tumorigenesis (Hansell and others 1995; others 1990, 1991; Sharpe and others 1990) . In contrast, IL-8 (ELR + ) was the first CXC chemokine found to induce angiogenesis. IL-8 was shown to mediate both in vitro endothelial cell chemotactic and proliferative activity as well as in vivo angiogenesis in the absence of preceding inflammation using bioassays of angiogenesis (Hu and others 1993; Koch and others 1992; Strieter and others 1992) . These findings have been substantiated by other investigations, which have shown that IL-8, similar to bFGF or VEGF, induces endothelial cell tube formation in vitro and angiogenesis in vivo (Norrby 1996; Yoshida and others 1997) . These experiments prove that IL-8 has a direct effect on the endothelial cell and that this angiogenic activity is distinct from its ability to induce inflammation. These findings suggest that members of the CXC chemokine family function in a disparate manner and can behave as either potent angiogenic or angiostatic factors in regulating net neovascularization.
Based on this contention, we hypothesized that the highly conserved ELR motif of several members of the CXC chemokine family is a structural/functional domain that dictates their angiogenic activity. To test this postulate, endothelial cell chemotaxis was performed in the presence or absence of varying concentrations of ELR + or ELR-CXC chemokines to ascertain whether CXC chemokines display disparate angiogenic activity. All of the ELR + CXC chemokines tested demonstrated significant endothelial cell chemotactic activity over background, whereas the endothelial cell chemotactic activity of ELR-CXC chemokines was similar to background (Strieter and others 1995) . Moreover, ELR" CXC chemokines inhibited endothelial cell chemotactic response to ELR + CXC chemokines, bFGF, or VEGF. This was further confirmed in vivo using the CMP assay of neovascularization (Strieter and others 1995) (Table 3) . To establish that the ELR motif is the critical structural/functional domain that dictates angiogenic activity for members of the CXC chemokine family, sitedirected mutants were constructed that contained amino acid residue substitutions for the ELR motif of wild-type IL-8 (Strieter and others 1995) . In addition, a site-directed mutant of MIG was produced containing the ELR motif immediately adjacent to the first cysteine amino acid residue of the primary structure of MIG (Strieter and others 1995) . Endothelial cell chemotaxis and the CMP assay were used to assess the biological activity of these mutants. Both IL-8 mutants failed to induce endothelial cell migration; however, both mutants inhibited the maximal endothelial chemotactic activity of wild-type IL-8 and bFGF (Strieter and others 1995) . In addition, both IL-8 mutants inhibited the angiogenic response of either wild-type IL-8 or ENA-78, or bFGF in the CMP assay (Strieter and others 1995) . In contrast, the ELR + mutant of wild-type MIG induced a significant angiogenic response, and wild-type MIG inhibited the angiogenic response of this mutant in the CMP assay (Strieter and others 1995) . These findings suggest a structural/functional role of the ELR motif in determining the angiogenic or angiostatic potential of CXC chemokines, supporting the hypothesis that the net biological balance between angiogenic and angiostatic CXC chemokines may play an important role in regulating overall tumor-associated angiogenesis. 
ELR + CXC Chemokines Promote Angiogenesis Associated with Tumorigenesis
The CXC chemokines are clearly important mediators of tumorigenesis related to their angiogenic properties. Although GRO-P has been recently reported to inhibit angiogenesis (Cao and others 1995) , the concentration used in this study was 1000-fold greater (1 to 10 uM) than that found for its angiogenic activity (1 to 10 nM) (Arenberg and others 1997; Strieter and others 1995) . This finding suggests that superphysiological concentrations of GRO-|3 can "desensitize" the angiogenic response. Moreover, studies in melanoma support that all GROs play a significant role in mediating tumorigenesis related to both their mitogenic and angiogenic activities. For example, GRO-a, p\ and y are all found to be highly expressed in human melanoma specimens (Luan and others 1997) . To determine the biological significance of the presence of these ELR + CXC chemokines in melanoma, human GRO-a, |3, and y genes were transfected into immortalized murine melanocytes (Luan and others 1997; Owen and others 1997) . The continuous expression of any of these GROs in the cells transformed their phenotypic behavior, allowing them to form large colonies in soft agar in vitro and to generate tumors in vivo in both nude and SCID mice (Luan and others 1997; Owen and others 1997) . The tumors that formed were highly vascular and similar to the vascularity of B16 melanoma controls (Luan and others 1997; Owen and others 1997) . Passive immunization of tumor-bearing animals with specific anti-GRO antibodies resulted in a marked reduction of tumor-derived angiogenesis and inhibition of tumor growth (Luan and others 1997; Owen and others 1997) . These findings support the notion that the ELR + CXC chemokines, such as GRO-a, (3, and y, have the ability to act as potent angiogenic factors to promote tumorigenesis in melanoma.
The progression and growth of ovarian carcinoma are also dependent on successful angiogenesis, and IL-8 has been determined to play a significant role in mediating human ovarian carcinoma-derived angiogenesis and tumorigenesis in nude mice (Yoneda and others 1998) . Yoneda and associates (1998) examined the expression of IL-8, bFGF, and VEGF in five different human ovarian carcinoma cell lines. All cell lines expressed similar levels of bFGF in vitro; however, these cells expressed either high or low levels of EL-8 or VEGF. High-expressing EL-8 tumors were very aggressive, resulting in a high mortality rate that was tied to marked neovascularization (Yoneda and others 1998) . The expression of IL-8 was directly correlated with neovascularization and inversely correlated with survival, whereas VEGF expression was correlated only with production of ascites (Yoneda and others 1998) . No correlation was found for the expression of bFGF with either tumor neovascularization or survival (Yoneda and others 1998) . These studies have also been substantiated in gastric carcinoma and melanoma, in which the expression of EL-8 correlates with vascularity, tumorigenicity, and metastatic properties of these tumors (Kitadai and others 1998; Singh and others 1994) .
EL-8 has been found in specimens of non-small cell lung cancer (NSCLC 1 ) (Smith and others 1994) and has been determined to be a significant angiogenic factor contributing to overall tumor-derived angiogenic activity (Arenberg and others 1996a; Smith and others 1994) . Extending these studies to an in vivo model system of human tumorigenesis (namely, human NSCLC/SCID mouse chimera) (Arenberg and others 1996a), tumor-derived IL-8 was found to be directly correlated with tumorigenesis (Arenberg and others 1996a). Tumor-bearing animals treated with neutralizing antibodies to EL-8 demonstrated a >40% reduction in tumor growth, which was paralleled by a reduction in spontaneous metastases to the lung (Arenberg and others 1996a) . The attenuation of tumor growth and metastases was directly correlated with reduced tumor-derived angiogenesis. These findings have been corroborated using other NSCLC cell lines. Yatsunami and associates (1997) determined that NSCLC cell lines that constitutively express IL-8 have greater tumorigenic potential in nude mice, and this property is directly correlated with their angiogenic activity.
Although IL-8 may represent an important angiogenic CXC chemokine, ENA-78 may be a more important angiogenic CXC chemokine than IL-8 in NSCLC (Arenberg and others 1998) . Human surgical specimens of NSCLC tumors were found to display a direct and significant correlation of ENA-78 protein levels with tumor neovascularization. The biological relevance of this finding was confirmed in a SCID mouse model of human tumorigenesis using human NSCLC cell lines. ENA-78 expression in tumors was directly correlated with tumor growth. Moreover, when human NSCLC tumor-bearing animals were passively immunized with anti-ENA-78, both tumor growth and spontaneous metastases were markedly attenuated. The reduction in tumor growth was accompanied by a marked decrease in tumor vascularity and an increase in apoptosis of the tumor cells. The apoptosis of these cells was not due to a direct effect of depletion of ENA-78 because there was no in vitro evidence that ENA-78 had any effect on apoptosis. This belief is consistent with the fact that angiostatic therapy of tumors is associated with increased tumor cell apoptosis others 1996, 1997) . Similarly, in vivo and in vitro proliferation of NSCLC cells was unaffected by the presence of anti-ENA-78 to "deplete" endogenous ENA-78. Although there was a significant correlation of ENA-78 expression with tumor vascularity and tumorigenesis, neutralization of ENA-78 did not completely inhibit tumor growth. This finding potentially reflects the fact that angiogenic activity induced by NSCLC tumors is probably due to many overlapping or redundant factors acting in a parallel manner. In addition to ENA-78 and IL-8, there are perhaps other angiogenic factors that have not been accounted for, including other ELR + CXC chemokines (GROs or GCP-2) and/or non-CXC chemokine angiogenic factors (bFGF or VEGF). Nevertheless, the findings that ELR+ CXC chemokines represent significant angiogenic factors in human tumors suggest that strategies targeting angiogenic CXC chemokine-mediated angiogenesis may be a novel treatment approach to various cancers.
ELR' CXC Chemokines Attenuate Angiogenesis Associated with Tumorigenesis
The antithesis of ELR + is the function of ELR-CXC chemokines in regulating angiogenesis. Burkitt's lymphoma cell lines form angiogenesis-dependent tumors in nude mice (Gurtsevitch and others 1988) . To determine whether IP-10 or MIG regulates the angiogenic activity of Burkitt's lymphomas, Sgadari and associates (1996) implanted several of these tumor cell lines in nude mice. The expression of IP-10 and MIG was greater in the tumors that demonstrated spontaneous regression compared with those tumors that grew significantly in nude mice. The regression of the tumors was directly related to evidence of reduced angiogenesis, increased tumor vascular damage, and tissue necrosis. To determine whether this effect was related to IP-10 or MIG, Burkitt's lymphoma cell lines grown in nude mice were subjected to intratumor inoculation with IP-10 or MIG. Both conditions resulted in marked reduction in tumor-associated angiogenesis (Sgadari and others 1997; Teruya-Feldstein and others 1997) . Although both IP-10 and MIG can induce T-cell recruitment via the interaction with their putative CXC chemokine receptor (CXCR3) (Baggiolini 1998; Baggiolini and others 1997; Farber 1997; Luster 1998; Rollins 1997) , the ability of both of these ELR-CXC chemokines to inhibit angiogenesis and induce lymphoma regression in nude mice supports the thinking that these chemokines mediate their effects in a T-cell-independent manner.
Our laboratory has examined the role of IP-10 in regulating angiogenesis associated with NSCLC (Arenberg and others 1996b) . The levels of IP-10 from human surgical tumor specimens were significantly higher than in normal lung tissue. The increase in IP-10 from human NSCLC tissue was entirely attributable to the higher levels of IP-10 present in squamous cell carcinoma (SCCA 1 ) compared with adenocarcinoma. Moreover, depletion of IP-10 from SCCA surgical specimens resulted in augmented angiogenic activity (Arenberg and others 1996b) . The marked difference in the levels and bioactivity of IP-10 associated with SCCA, compared with adenocarcinoma, is pathophysiologically relevant and represents a possible mechanism for the biological differences of these two cell-types of NSCLC. Compared with SCCA of the lung, patient survival is lower, metastatic potential is higher, and evidence of angiogenesis is greater for adenocarcinoma (Carney 1988; Minna 1991; Yuan and others 1995) .
The studies described above were extended to a SCID mouse model system to examine the effect of IP-10 on human NSCLC cell line tumor growth in a T-and B-cell-independent manner. SCID mice were inoculated with either A549 (adenocarcinoma) or Calu-1 (SCCA) cells (Arenberg and others 1996) . The production of IP-10 from A549 and Calu-1 tumors was inversely correlated with tumor growth (Arenberg and others 1996b) ; however, IP-10 levels were significantly higher in the Calu-1 compared with A549 tumors. The appearance of spontaneous lung metastases in SCID mice bearing A549 tumors occurred after IP-10 levels from either the primary tumor or plasma reached a nadir. In subsequent experiments, SCID mice bearing Calu-1 tumors were treated with either neutralizing anti-IP-10 to deplete endogenous IP-10, whereas, animals bearing A549 tumors were treated with intratumor IP-10 to "reconstitute" IP-10. Depletion of IP-10 in Calu-1 tumors resulted in a two-fold increase in their size at 10 wk. In contrast, reconstitution of intratumor IP-10 in A549 tumors reduced both their size and metastatic potential, which was directly attributable to a reduction in tumor-associated angiogenesis (Figure 2 ). These findings support the notion that tumor-derived IP-10 is an important endogenous angiostatic factor in NSCLC, and treatment strategies designed to reconstitute IP-10 and/or other angiostatic CXC chemokine may lead to marked tumor regression. 
Conclusion
Angiogenesis is regulated by an opposing balance of angiogenic and angiostatic factors. The studies described above using immunodeficient mice as animal models of human tumorigenesis have demonstrated that CXC chemokines appear to be important endogenous factors that regulate angiogenesis in association with tumorigenesis in a variety of cancers. These findings support the notion that therapy directed at either inhibition of angiogenic or augmentation of angiostatic CXC chemokine biology may be a novel approach in the treatment of human tumors. Furthermore, the ability to study these molecules in immunodeficient mice has allowed us to assess the biology of human CXC chemokines in the regulation of angiogenesis in a T-and B-cell-independent manner in the context of human tumorigenesis.
